Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label adjunctive retigabine with specified antiepileptic monotherapy in adults with partial-onset seizures
2009-017744-14Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of retigabine in epilepsy and Focal Onset Epilepsy (4 arms), sponsored by GSK. Primary endpoint: 50% responder rate in 28-day partial-onset seizure frequency. Started Mar 2010; status: completed.
02
Drugs
retigabine
03
Conditions
epilepsyFocal Onset Epilepsy
Beyond the preview
Go deeper on 2009-017744-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017744-14.